Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supernus PharmaceuticalsLTS:0LB2 +1.55%87 EV-to-EBITDA is 54.02 as of Jul. 29, 2026, which is 295% above its 10-year median of 13.69. GuruFocus rates LTS:0LB2 with a GF Score™ of 87/100 and a GF Value™ of $41.79 (Modestly Overvalued). Among 744 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 90.19% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Supernus Pharmaceuticals's enterprise value is $2,427.5 Mil.
Supernus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $44.9 Mil. Therefore, Supernus Pharmaceuticals's EV-to-EBITDA for today is 54.02.
The historical rank and industry rank for Supernus Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
LTS:0LB2'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.94 Med: 13.69 Max: 67.57
Current: 54.02
During the past 13 years, the highest EV-to-EBITDA of Supernus Pharmaceuticals was 67.57. The lowest was 4.94. And the median was 13.69.
LTS:0LB2's EV-to-EBITDA is ranked worse than 90.19% of 744
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs LTS:0LB2: 54.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Supernus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Supernus Pharmaceuticals's share price for today is $48.56.
Supernus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LB2 vs RGC, BCRX, PBH: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's EV-to-EBITDA falls into.
Supernus Pharmaceuticals's current Enterprise Value is $2,427.5 Mil.
Supernus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $44.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a EV-to-EBITDA of 54.02 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Supernus Pharmaceuticals. This is 295% above median its historical median of 13.69. Over the past decade, Supernus Pharmaceuticals' EV-to-EBITDA has ranged from 4.94 to 67.57. According to the industry distribution chart, Supernus Pharmaceuticals ranks #671 out of 744 companies in the Drug Manufacturers industry, placing it in the top 90.2%.
Is Supernus Pharmaceuticals' EV-to-EBITDA too high?
Supernus Pharmaceuticals' current EV-to-EBITDA of 54.02 is 295% above median its 10-year median of 13.69. Over the past 10 years, this metric has ranged from a low of 4.94 to a high of 67.57. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Supernus Pharmaceuticals' value of 54.02 is 316.2% above this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #671 out of 744 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' EV-to-EBITDA compare to RGC and BCRX?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #671 out of 744 companies for EV-to-EBITDA. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.98. Supernus Pharmaceuticals' value of 54.02 is 316.2% above this benchmark. Historically, Supernus Pharmaceuticals' own EV-to-EBITDA has ranged from 4.94 to 67.57 over the past decade. While the company's 10-year median is 13.69 vs. the industry median of 12.98, Supernus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 744 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current EV-to-EBITDA of 54.02 is 316.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Supernus Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current EV-to-EBITDA is 54.02, which is 295% above median its own 10-year median of 13.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $41.79, compared to a current price of $48.56 — trading 16.2% above its estimated fair value. The current EV-to-EBITDA is 54.02, which is 295% above median its 10-year median of 13.69 and 316.2% above the Drug Manufacturers industry median of 12.98. Supernus Pharmaceuticals' overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current EV-to-EBITDA is 54.02 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $48.56 is trading 16.2% above its estimated GF Value™ of $41.79.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
EV-to-EBITDA: 54.02 (295% above median its 10-year median of 13.69)
GF Value™: $41.79 vs. price of $48.56 (16.2% above fair value)
Industry Position: 316.2% above the Drug Manufacturers median (#671 of 744)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score
Get the complete analysis for LTS:0LB2
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
